Patients with INOCA (Ischemia and No Obstructive Coronary Artery Disease) suffer from high readmission rates and high costs. INOCA is widespread: it affects two-thirds of cardiac patients and four times as many women as men.
Echopoint are addressing this problem.
Our first-in-human study is in progress at Barts Heart Centre in London, UK
Prof. Andreas Baumbach
Chair of Device Innovation, Barts Health NHS Trust
Dr. Dan Jones
Consultant Interventional Cardiologist and Senior Lecturer, Barts Health NHS Trust
Dr. Vincent McCaughan
Chief Registrar, Interventional Cardiology, Barts Health NHS Trust
References
Kunadian V., et al., An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group, European Heart Journal, Volume 41, Issue 37, 1 October 2020, Pages 3504–3520, https://doi.org/10.1093/eurheartj/ehaa503